A Phase I/II Dose Escalation and Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of TJ011133 in Combination With Toripalimab in Subjects With Advanced Solid Tumors
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Lemzoparlimab (Primary) ; Toripalimab (Primary)
- Indications Gastric cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors I-MAB Biopharma; TJ Biopharma
- 08 Feb 2023 Status changed from recruiting to discontinued.
- 18 Jan 2022 According to an I-MAB Biopharma media release, phase 2 study is designed as a basket trial and could potentially lead to a registrational trial in China.
- 18 Jan 2022 According to an I-MAB Biopharma media release, first patient has been dosed in this trial.